Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (754)	4/7/2003 11:37:44 AM
From: tuck	Respond to of 7424

The hype now is to find a partner for it. from their website: >>Curis has developed one of the small molecule Hh inhibitors (CUR-61414) to the point of IND acceptance and is now seeking a partner with dermatological clinical expertise to complete the evaluation of human therapeutic safety and efficacy.<< Cheers, Tuck

To: Icebrg who wrote (754)	4/22/2003 6:05:07 PM
From: Icebrg	Read Replies (2) \| Respond to of 7424

Are happy days here again? Entremed (ENMD) was up 153 % today after a pressrelease on some preclinical data. The drug is actually already in phase II. So far without producing - as far as I know - anything note-worthy. At least as far as treatment effects are concerned. The traded volume was (according to Yahoo) 8.545.255 shares compared with the one-year daily average of 66.590. Considering the clouds shading the company's immediate financial future the enthusiasm shown is a little bit difficult to understand. Do these clouds indeed have a silver lining, or...? Erik